SAN DIEGO-- (BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced results from a prospective, multicenter, single-arm study ...

Tandem Diabetes Care has received approval from the US Food and Drug Administration (FDA) for its Control-IQ+ automated insulin delivery technology to be used during pregnancy in individuals with type ...

– Tandem Diabetes Care, a leader in insulin delivery and diabetes technology announced the U.S. commercial launch of Control-IQ+ technology. – This update provides users with greater flexibility and ...

Managing type 1 diabetes during pregnancy is a high-stakes balancing act where glycemic goals are significantly tighter than for the general population. Historically, expectant mothers have had to ...

SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, today announced that its next-generation automated insulin delivery ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

A greater proportion of patients with type 1 diabetes who used automated insulin delivery systems vs multiple daily injections achieved the Healthcare Effectiveness Data and Information Set (HEDIS) ...

"The greatest benefit was observed in participants with the worst baseline glycemic control, in whom the auto-bolus feature of the Control-IQ algorithm appears to have substantial impact," wrote the ...

The FDA expansion came after Tandem and Dexcom published a study earlier this year focusing specifically on toddlers’ use of their combined automated insulin delivery system. After 13 weeks, kids saw ...

– Enhanced features extend automated insulin delivery (AID) to people ages 2 years and older with type 1 diabetes and adults with type 2 diabetes – Control-IQ+ automated insulin delivery technology ...